PTPN11
Aliases:
This biomarker is also known as:- PTP-1D
- protein-tyrosine phosphatase 1D
- Noonan syndrome 1
- Protein-tyrosine phosphatase 1D
- EC 3.1.3.48
- SHP-2
- PTP2C
- SHP2
- protein tyrosine phosphatase, non-receptor type 11
- NS1
- SH-PTP2
- Shp2
- CFC
- PTPN11
- BPTP3
- Protein-tyrosine phosphatase 2C
- PTP-2C
- SH-PTP3
- tyrosine-protein phosphatase non-receptor type 11
- SHPTP2
- protein-tyrosine phosphatase 2C
Description…
PTPN11 is a member of the protein tyrosine phosphatase (PTP) family. PTP family members are a group of enzymes that catalyze the removal of phosphate groups from tyrosine residues by the hydrolysis of phosphoric acid monoesters. The activity of PTPs opposite that of kinases and phosphorylases and therefore PTPs play an integral role in many signal transduction pathways. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. PTPN11 is widely expressed in most tissues and plays a regulatory role in various cell signaling events that are important for a diversity of cell functions, such as mitogenic activation, metabolic control, transcription regulation, and cell migration.
Datasets
There are no datasets associated with this biomarker.
Attributes
QA State: | Curated |
---|---|
Type: | Protein |
HGNC Name: | PTPN11 |
The following organs have data associated with this biomarker…
Attributes
Phase: | 2 |
---|---|
QA State: | Under Review |
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access to this biomarker.
- Multianalyte tests for the early detection of cancer: speedbumps and barriers.
- Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
- TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.